Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction

Heart Failure Reviews

Volumn 9, Issue 2, 2004, Pages 107-113

  Thattassery, Emil ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Beta blocker; Heart failure; Left ventricular systolic dysfunction; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PLACEBO; PROPRANOLOL; RAMIPRIL; TIMOLOL; VALSARTAN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DEFIBRILLATOR; DEPRESSION; DOSE CALCULATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; FATIGUE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMPLANTATION; LONG TERM CARE; META ANALYSIS; MORTALITY; SEXUAL DYSFUNCTION;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 8544260390     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000046365.53467.f4     Document Type: Article

References (37)

1. Borrello F, Beahan M, Klein L, Gheorghiade M. Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. Am J Cardiol 2004;93:21-29.
2. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: The National Registry of Myocardial Infarction. Circulation 2002;105:2605-2610.
3. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004;109:494-499.
4. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol 2003 ;91:18-40.
5. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003;107:1570-1575.
6. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. J Am Coll Cardiol 1997;29:229-236.
7. Spargias KS, Hall AS, Greenwood DC, Ball SG. Beta-blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: Evidence from the AIRE study. Heart 1999;81:25-32.
8. Kober L, Torp-Pedersen C, Jorgensen S, Eliasen P, Camm AJ. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Am J Cardiol 1998;81:1292-1297.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 334:1349-1355.
10. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
11. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
12. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
13. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation 2002;106:394-398.
14. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: Systematic review and meta-regression analysis. BMJ 1999;318:1730-1737.
15. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
16. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
17. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results ofthe thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618-627.
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
19. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-1714.
20. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.;21 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: Executive Summary
21. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.;
22. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104(24):2996-3007.
23. Stroe AF, Gheorghiade M. Carvedilol: Beta-blockade and beyond. Rev Cardiovasc Med 2004;5 (Suppl 1):S18-S27.
24. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
25. Boissel JP, Leizorovicz A, Picolet H, Ducruet T. Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. Am J Cardiol 1990;66:24C-31C.
26. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985;6:199-226.
27. Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol 1997;80:40J-44J.;
28. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction: Tolerability and survival effects. Am J Cardiol. 1993; 71(9):39C-44C.
29. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-1390.;
30. Torp-Pedersen C, Kober L, Ball S, et al. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). Eur J Heart Fail 2002;4(4):495-499.
31. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.;
32. Gattis WA, O'Connor CM, Gallup DS, Hasselblad AV, Gheorghiade M; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43(9):1534-1541.
33. Saunders E, Gavin JR, III. Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 2003;5:12-17.
34. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993 45:95-100.
35. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
36. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
37. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.